In This Article:
SCYNEXIS (NASDAQ:SCYX) Third Quarter 2024 Results
Key Financial Results
-
Revenue: US$660.0k (down 63% from 3Q 2023).
-
Net loss: US$2.81m (loss widened by 60% from 3Q 2023).
-
US$0.058 loss per share (further deteriorated from US$0.037 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
SCYNEXIS EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 87%. Earnings per share (EPS) exceeded analyst estimates by 38%.
Looking ahead, revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US.
Performance of the American Pharmaceuticals industry.
The company's shares are down 2.2% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 2 warning signs for SCYNEXIS that you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.